Philogen S.p.A.

Philogen S.p.A. is a dynamic Swiss-Italian biotechnology company dedicated to the development of innovative biopharmaceuticals for angiogenesis-related disorders. Founded in 1996, Philogen S.p.A. has pioneered the isolation, engineering, and clinical advancement of leading products that target angiogenesis in-vivo. Their groundbreaking work has demonstrated the effectiveness of human monoclonal antibodies in selectively targeting tumor neo-vasculature.

With headquarters in Sovicille, SIENA, at Loc. Bellaria, 35, 53018, IT, and an additional location in Monteriggioni, Siena, at Loc.Montarioso, 11, 53035, IT, Philogen S.p.A. operates with a commitment to excellence. Philogen S.p.A. generates revenue through diverse activities, including agreements with major pharmaceutical companies and a robust portfolio of international patents. The company's Zurich-based R&D unit, Philochem, focuses on isolating promising candidate products, while the Siena facility adheres to GMP standards for pharmaceutical production and clinical trials.

Philogen S.p.A. continues to advance its pipeline of anti-cancer antibody derivatives and a treatment for rheumatoid arthritis through clinical studies, with registrational studies on the horizon. Philogen S.p.A. is dedicated to pushing the boundaries of biotechnology and improving patient outcomes. We invite the manager of Philogen S.p.A. to create a customized and exclusive company showcase and product listing on our platform.